Literature DB >> 18657146

Effect of combined oral contraceptives on breast epithelial proliferation in young women.

Debora Garcia y Narvaiza1, Maria Alicia H Navarrete, Roberto Falzoni, Carolina M Maier, Afonso C P Nazário.   

Abstract

The mammary gland undergoes morphologic changes during the menstrual cycle. Proliferation of normal breast epithelium is most extensive during the natural luteal phase. To determine the impact of one cycle of a combined oral contraceptive (COC) on breast homeostasis, we evaluated the proliferation index (PI), determined by KI-67 expression, in normal human mammary epithelial cells and correlated it with cellular proliferation in spontaneous menstrual cycles during the same period. Normal breast tissue samples were obtained from 82 patients randomized in two groups. Forty-two women in group A received one cycle of a COC (30 mug ethinyl estradiol and 150 mug levonorgestrel) administrated daily for 21 days, beginning on the first day of the menstrual cycle. Group B patients (n = 40) experienced a natural menstrual cycle. Menstrual cycle phase characterization was based on the date of the last period and subsequent menses and on progesterone serum levels obtained at the time of biopsy. The PI (number of Ki-67-positive nuclei per 1,000 epithelial cells), was significantly larger in group A (5.47 +/- 3.87), than in group B (3.27 +/- 3.24), p < 0.01. A cyclical variation of PI was observed in COC cycles. The rise in PI in the first week of the COC cycles was significantly higher than in the natural cycle (COC = 7.02 +/- 4.94; non-COC = 1.10 +/- 0.67; p < 0.0011). There was no significant difference between the two groups during the other weeks. Additionally, there was an inverse correlation between proliferation and chronological age, irrespective of the stage of the cycle. The PI of COC (p = 0.175) and natural cycles (p = 0.466) were not statistically different in younger patients. COC users have increased proliferative activity at the beginning of the menstrual cycle. This alteration in the pattern of proliferative activity may relate to the increased risk of breast cancer that has been associated with COCs.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18657146     DOI: 10.1111/j.1524-4741.2008.00621.x

Source DB:  PubMed          Journal:  Breast J        ISSN: 1075-122X            Impact factor:   2.431


  9 in total

1.  Oral contraceptives and breast cancer risk overall and by molecular subtype among young women.

Authors:  Elisabeth F Beaber; Kathleen E Malone; Mei-Tzu Chen Tang; William E Barlow; Peggy L Porter; Janet R Daling; Christopher I Li
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-03-14       Impact factor: 4.254

Review 2.  MALDI imaging mass spectrometry of human tissue: method challenges and clinical perspectives.

Authors:  Erin H Seeley; Richard M Caprioli
Journal:  Trends Biotechnol       Date:  2011-02-02       Impact factor: 19.536

3.  Recent Use of Oral Contraceptives and Risk of Luminal B, Triple-Negative, and HER2-Overexpressing Breast Cancer.

Authors:  Nicole C Lorona; Linda S Cook; Mei-Tzu C Tang; Deirdre A Hill; Charles L Wiggins; Christopher I Li
Journal:  Horm Cancer       Date:  2019-04-15       Impact factor: 3.869

4.  Oral contraceptive use and breast cancer: a prospective study of young women.

Authors:  David J Hunter; Graham A Colditz; Susan E Hankinson; Susan Malspeis; Donna Spiegelman; Wendy Chen; Meir J Stampfer; Walter C Willett
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-08-27       Impact factor: 4.254

5.  Lowering oral contraceptive norethindrone dose increases estrogen and progesterone receptor levels with no reduction in proliferation of breast epithelium: a randomized trial.

Authors:  Linda Hovanessian-Larsen; DeShawn Taylor; Debra Hawes; Darcy V Spicer; Michael F Press; Anna H Wu; Malcolm C Pike; C Leigh Pearce
Journal:  Contraception       Date:  2012-02-09       Impact factor: 3.375

6.  Associations of Oral Contraceptives with Mammographic Breast Density in Premenopausal Women.

Authors:  Lusine Yaghjyan; Carmen Smotherman; John Heine; Graham A Colditz; Bernard Rosner; Rulla M Tamimi
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2021-12-03       Impact factor: 4.090

7.  Recent oral contraceptive use by formulation and breast cancer risk among women 20 to 49 years of age.

Authors:  Elisabeth F Beaber; Diana S M Buist; William E Barlow; Kathleen E Malone; Susan D Reed; Christopher I Li
Journal:  Cancer Res       Date:  2014-08-01       Impact factor: 12.701

8.  Investigation on the association between breast cancer and consumption patterns of combined oral contraceptive pills in the women of Isfahan in 2011.

Authors:  Soheila Ehsanpour; Fahime Seyed Ahmadi Nejad; Fariborz Mokarian Rajabi; Fariba Taleghani
Journal:  Iran J Nurs Midwifery Res       Date:  2013-05

Review 9.  Polycystic Ovary Syndrome in Adolescents: Challenges in Diagnosis and Treatment.

Authors:  Fahimeh Ramezani Tehrani; Mina Amiri
Journal:  Int J Endocrinol Metab       Date:  2019-07-27
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.